Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors

NCT00708773 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT00708773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00708773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2006
Completion date
August 31, 2016
Enrollment
68 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer